SUMMARY
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized COVID-19 patients. Integrated analysis using k-means reveal four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors are delineated by high and low antibody responses. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4+ T cell frequencies. These data suggest that the “Interferon paradox” previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.
Competing Interest Statement
J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. TN has received speaking fee from Boehringer Ingelheim for the talks unrelated to this research. These agencies had no role in the design, implementation, or interpretation of this study. The authors declare that they have no other competing interests.
Funding Statement
This study was funded by the American Foundation for AIDS Research (amfAR) grant 110068-68-RGCV (DEK, NC, AF); Canada s COVID-19 Immunity Task Force (CITF), in collaboration with the Canadian Institutes of Health Research (CIHR) grant VR2-173203 (DEK, AF); CIHR grant # 178344 (DEK, AF); CIHR grants 365825 and 409511 (JBR); Canada Foundation for Innovation (CFI): Exceptional Fund COVID-19 grant #41027 to AF, DEK, NC; CFI leader to JBR. The Symphony flow cytometer was funded by a John R. Evans Leaders Fund from the Canada Foundation for Innovation (#37521 to D.E.K) and the Fondation Sclerodermie Quebec. The Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation (AF), CRCHUM Foundation. The Biobanque Quebecoise de la COVID-19 (BQC19) is supported by the Fonds de recherche Quebec Sante (FRQS) Genome Quebec and the Public Health Agency of Canada. DEK and JBR are FRQS Merit Research Scholars. NC, MD, MC, JBR, CL and MT are supported by FRQS Salary Awards. AF and AP are recipients of Canada Research Chairs. EBR is recipient of a COVID-19 excellence scholarship from the Universite de Montreal (EBR); SM is recipient of an IVADO MSc Excellence scholarship and a Fonds de recherche du Quebec Nature et technologies (FRQNT) B1X scholarship (SM); HER is supported by a National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award (F31-HL156419); SPA, J.P., M.B. were supported by CIHR fellowships; G.S is supported by a FRQS doctoral fellowship and by a scholarship from the Department of Microbiology, Infectious Disease, and Immunology of the University of Montreal. The Pronmed study was funded by the SciLifeLab/Knut and Alice Wallenberg national COVID-19 research program (M.H.: KAW 2020.0182, KAW 2020.0241), the Swedish Heart-Lung Foundation (M.H.: 20210089, 20190639, 20190637), the Swedish Research Council (R.F.: 2014-02569, 2014-07606), the Swedish Kidney Foundation (R.F.: F2020-0054) and the Swedish Society of Medicine (M.H.: SLS-938101). Funding bodies had no role in the design of the study, data collection, interpretation, or in the writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For participants enrolled in Quebec, the study was approved by the IRBs of the University of Montreal Hospital and the Jewish General Hospital (multicentric protocol: MP-02-2020-8929) and written informed consent obtained from all participants or, when incapacitated, their legal guardian before enrollment and sample collection. Research adhered to the standards indicated by the Declaration of Helsinki. For the validation cohort recruited at Uppsala University Hospital in Sweden, the study was approved by the Swedish National Ethical Review Agency (Pronmed study; 2017-043, amended 2019-00169, 2020-01623, 2020-05730 and 2022-00526-01) and registered a priori at ClinicalTrials.gov (NCT03720860). Informed consent was obtained from the patient or next of kin if the patient was unable to give consent. The Declaration of Helsinki and subsequent revisions were followed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from the Pronmed study is available from the SciLifeLab data repository after appropriate permissions and data access agreements (https://doi.org/10.17044/scilifelab.14229410). Data from the BQC-19 repository is available after appropriate permissions and data access agreements (https://en.quebeccovidbiobank.ca).
